Overview

Safety and Efficacy of Oral Etoposide Combined With Antirotinib and Envollizumab in Elderly Patients With Lung Cancer

Status:
Not yet recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
This study aims to explore the safety and efficacy of etoposide capsules combined with anrotinib and Envollizumab in elderly patients with extensive small cell lung cancer.This is a single-center, single-arm exploratory clinical study. 30 patients with extensive small-cell lung cancer are scheduled to be enrolled. Treatment regimen is etoposide capsule 100mg PO qd*7d, antirotinib 12mg PO qd*14d, Emvolizumab 300mg/ IH Q3W, every 21 days, until disease progression or intolerable adverse reactions or death.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital